CVS has received price target upgrades from Mizuho and Bernstein, which reiterated an Outperform rating and sees the company well-positioned for a Medicare Advantage turnaround. The stock is trading near its 52-week high, indicating investor confidence. However, CVS faces legal challenges, including a lawsuit from hospitals over 340B drug pricing and a Tennessee law suit regarding pharmacy ownership.